Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorQilu Hospital of Shandong University

About this trial

The study objective is to evaluate the relative merits, safety and effectiveness of Anti-reflux mucosal valvuloplasty (ARMV) in GERD patients currently treated with daily Proton Pump Inhibitors (PPIs).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

18-60 years of age;

Hiatal hernia ≤ 2 cm;

Sliding hernia ≤ 2 cm;

Recurrence of GERD symptoms after cessation of PPIs;

Disqualifiers

BMI > 35 kg/m2;

ASA > II;

Barrett's esophagus;

Hiatal hernia > 2 cm;

Trial design

Design model

Parallel

Treatments tested in this trial

  • anti-reflux mucosal valvuloplasty (ARMV)

    Procedure/Surgery

    During the ARMV procedure, a segment of the mucosa at the esophagogastric junction (EGJ) is released and reconstructed to form a mucosal flap. Cautery markings are made on 3/4-4/5 of the mucosa along the lesser curvature, approximately 2 cm below the dentate line. After submucosal injection of saline with indigocarmine, the premarked mucosa is dissected from the caudal to cranial side using an endoscopic submucosal dissection technique. The cranial edge of the released mucosa is left in place, and the semi-free mucosa naturally curls to form a double-layer flap. Metal clips are then used to anchor the free edge of the mucosa to the exposed submucosa/smooth muscle to prevent flattening of the mucosal flap. Any visible bleeding on the exposed submucosa is coagulated using electric forceps.

Treatment groups

74 Participants
are divided into 2 treatment groups
Group A: ARMV (intervention group)Experimental treatment 1 intervention
Group B: PPI (control group)No intervention 0 interventions

Trial outcomes

Primary outcomes

1

GERD-HRQL

Questionnaire (GERD-HRQL) : Total Score: Calculated by summing the individual scores to questions 1-15 Greatest possible score (worst symptoms)= 75 Lowest possible score (no symptoms)= 0 Heartburn Score: Calculated by summing the individual scores to questions 1-6 . Worst heartburn symptoms = 30 No heartburn symptoms= 0 Scores of ≤ 12 with each individual question not exceeding 2 indicate heartburn elimination. Regurgitation Score: Calculated by summing the individual scores to questions10-15. Worst regurgitation symptoms = 30 No regurgitation symptoms = 0 Scores of ≤ 12 with each individual question not exceeding 2 indicate regurgitation elimination.

Time frame
at 0, 6 months follow- up

Secondary outcomes

1

GERD-Q score

Questionnaire (GERD-Q ) : Recall the frequency of burning sensation (heartburn) after your sternum in the past 7 days;How often do you feel stomach contents (liquid or food) returning to your throat or mouth (reflux) in the past 7 days?How often did you feel pain in the center of your upper abdomen in the past 7 days?How often did you feel nauseous in the past 7 days?How often have you had difficulty getting good night sleep due to heartburn and/or reflux in the past 7 days? Looking back on the past 7 days, in addition to the medication advised by the doctor, did you take additional medication to alleviate the frequency of heartburn and/or reflux? (such as calcium carbonate, aluminum hydroxide, and other antacids).0 days are 0 points, 1 day is 1 point, 2-3 days are 2 points, and 4-7 days are 3 points. Add up the scores for each item to obtain the total score.

Time frame
at 0, 3, 6 ,12 ,24,36 months follow- up
2

DeMeester score

Esophageal 24-hintraluminal ambulatory pH monitoring is performed to monitor the modality of the reflux. A catheter sensor is placed 5 cm above the proximal border of the lower esophageal sphincter (LES). Each reflux is considered acidic when the pH of the refluxate is less than 4. The acid reflux composite score (DeMeester score) is calculated using the following values: percentage of total time in reflux, percentage of time in reflux in the upright position, percentage of time in reflux in the supine position, the total number of reflux episodes, number of reflux episodes continuing over 5 minutes, and longest duration of reflux among all reflux episodes

Time frame
at 0, 6 and 24 months follow- up
3

Presence of reflux esophagitis

Healing of esophagitis will represent a clinically significant improvement. Treatment success will be defined by a significantly (p \< 0.05) higher number of patients with healed esophagitis in the ARMV group vs. PPI group.

Time frame
at 0, 6 and 24 months follow- up
4

Appearance of the mucosal flap

The shape and mobility of the anti-reflux mucosal flap displayed under endoscopy

Time frame
at 6 and 24 months follow- up

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.